{
    "root": "90a67c02-edce-44aa-8d3a-d819313acc26",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Valacyclovir",
    "value": "20250401",
    "ingredients": [
        {
            "name": "CROSPOVIDONE (120 .MU.M)",
            "code": "68401960MK"
        },
        {
            "name": "HYPROMELLOSE, UNSPECIFIED",
            "code": "3NXW29V3WO",
            "drugbank_id": "https://go.drugbank.com/drugs/DB11075"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30",
            "drugbank_id": "https://go.drugbank.com/drugs/DB14077"
        },
        {
            "name": "MICROCRYSTALLINE CELLULOSE",
            "code": "OP1R32D61U",
            "drugbank_id": "https://go.drugbank.com/drugs/DB14158"
        },
        {
            "name": "POLYSORBATE 80",
            "code": "6OZP39ZG8H",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_53426"
        },
        {
            "name": "POVIDONE, UNSPECIFIED",
            "code": "FZ989GH94E"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_32234"
        },
        {
            "name": "FD&C BLUE NO. 2",
            "code": "L06K8R7DQK"
        },
        {
            "name": "POLYETHYLENE GLYCOL, UNSPECIFIED",
            "code": "3WJQ0SDW1A",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_13643"
        },
        {
            "name": "VALACYCLOVIR HYDROCHLORIDE",
            "code": "G447S0T1VC",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_9919"
        }
    ],
    "indications": {
        "text": "valacyclovir tablet deoxynucleoside analogue dna polymerase inhibitor indicated : adult patients ( 1.1 ) \u2022 cold sores ( herpes labialis ) \u2022 genital herpes \u2022 treatment immunocompetent patients ( initial recurrent episode ) \u2022 suppression immunocompetent hiv-1-infected patients \u2022 reduction transmission \u2022 herpes zoster pediatric patients ( 1.2 ) \u2022 cold sores ( herpes labialis ) \u2022 chickenpox limitations ( 1.3 ) efficacy safety valacyclovir tablets established immunocompromised patients suppression genital herpes hiv-1-infected patients .",
        "doid_entities": [
            {
                "text": "cold (DOID:3083)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_3083"
            },
            {
                "text": "genital herpes (DOID:8704)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_8704"
            },
            {
                "text": "herpes zoster (DOID:8536)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_8536"
            },
            {
                "text": "chickenpox (DOID:8659)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_8659"
            }
        ],
        "orphanet_entities": []
    },
    "contraindications": {
        "text": "\u2022 valacyclovir tablets may given without regard meals . \u2022 valacyclovir oral suspension ( 25 mg/ml 50 mg/ml ) may prepared extemporaneously 500-mg valacyclovir tablets pediatric patients solid form appropriate [ ( 2.3 ) ] .",
        "doid_entities": [],
        "orphanet_entities": []
    },
    "warningsAndPrecautions": "valacyclovir tablets usp , 500 mg blue , film-coated , capsule shaped tablets , debossed ' ' one side '86 ' side . supplied bottle 30 ( ndc 82804-212-30 ) storage : store 20\u00b0 25\u00b0c ( 68\u00b0 77\u00b0f ) [ usp controlled room temperature ] . dispense well-closed container defined usp .",
    "adverseReactions": "valacyclovir tablets contraindicated patients demonstrated clinically significant hypersensitivity reaction ( e.g . , anaphylaxis ) valacyclovir , acyclovir , component formulation [ ( 6.3 ) ] .",
    "indications_original": "Valacyclovir tablet is a deoxynucleoside analogue DNA polymerase inhibitor indicated for: Adult Patients ( 1.1 ) \u2022 Cold Sores (Herpes Labialis) \u2022 Genital Herpes \u2022 Treatment in immunocompetent patients (initial or recurrent episode) \u2022 Suppression in immunocompetent or HIV-1-infected patients \u2022 Reduction of transmission \u2022 Herpes Zoster Pediatric Patients ( 1.2 ) \u2022 Cold Sores (Herpes Labialis) \u2022 Chickenpox Limitations of Use ( 1.3 ) The efficacy and safety of valacyclovir tablets have not been established in immunocompromised patients other than for the suppression of genital herpes in HIV-1-infected patients.",
    "contraindications_original": "\u2022 Valacyclovir tablets may be given without regard to meals.      \u2022 Valacyclovir oral suspension (25 mg/mL or 50 mg/mL) may be prepared extemporaneously from 500-mg valacyclovir tablets for use in pediatric patients for whom a solid dosage form is not appropriate     [see Dosage and Administration (       2.3)].",
    "warningsAndPrecautions_original": "Valacyclovir Tablets USP, 500 mg are blue, film-coated, capsule shaped tablets, debossed with 'I' on one side and '86' on other side. They are supplied in      Bottle of 30\u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0(NDC 82804-212-30)    \n                     \n                     Storage:     \n                     Store at 20\u00b0 to 25\u00b0C (68\u00b0 to 77\u00b0F) [see USP Controlled Room Temperature]. Dispense in a well-closed container as defined in the USP.",
    "adverseReactions_original": "Valacyclovir tablets are contraindicated in patients who have had a demonstrated clinically significant hypersensitivity reaction (e.g., anaphylaxis) to valacyclovir, acyclovir, or any component of the formulation     [see Adverse Reactions (       6.3)].",
    "drug": [
        {
            "name": "Valacyclovir",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_35854"
        }
    ]
}